Drug Profile
SPD 418
Latest Information Update: 16 Jan 2019
Price :
$50
*
At a glance
- Originator Shire Pharmaceuticals Group
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Epilepsy
Most Recent Events
- 08 Jan 2019 Shire has been acquired and merged into Takeda
- 27 Jul 2001 Discontinued-I for Epilepsy in USA (Unknown route)
- 07 Sep 2000 Phase-I clinical trials for Epilepsy in USA (Unknown route)